Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials

BACKGROUND: Anti-PD-1 monotherapy is the standard therapy for advanced melanoma patients, including those with NRAS mutations. The influence of NRAS mutation on immunotherapy, especially in noncutaneous melanoma, is largely uncharacterized. MATERIALS AND METHODS: We analyzed clinical data of four cl...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Immunol
Asıl Yazarlar: Zhou, Li, Wang, Xuan, Chi, Zhihong, Sheng, Xinan, Kong, Yan, Mao, Lili, Lian, Bin, Tang, Bixia, Yan, Xieqiao, Bai, Xue, Li, Siming, Guo, Jun, Cui, Chuanliang, Si, Lu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Immunology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8289467/
https://ncbi.nlm.nih.gov/pubmed/34290710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.691032
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller